Compare ACADIA Pharmaceuticals Inc. (ACAD) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs PulteGroup, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.9 (market cap $4.49B), while PulteGroup, Inc. trades at $123.54 (market cap $24.75B). The key difference: PulteGroup, Inc. is far larger — about 5.5× ACADIA Pharmaceuticals Inc.'s market cap, and PulteGroup, Inc. pays a 0.8% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | PHM | |
|---|---|---|
Market Cap | $4.49B | $24.75B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $142.56 |
52-Week Low | $20.06 | $108.00 |
Enterprise Value | $3.69B | $24.71B |
Dividend Yield | — | 0.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
PulteGroup (PHM) trades at $129.92, down 2.81% on the day, amid mixed earnings performance with recent quarterly misses. The stock shows a bullish technical signal with strong moving averages and oversold RSI levels, while fundamentals reflect solid profitability with a 12.14% net margin and attractive valuation at a P/E of 12.71. Recent corporate developments include land acquisition for a new community, signaling growth initiatives.
The outlook is cautiously optimistic, supported by analyst consensus and a $144.17 price target, but risks include margin pressure from incentives and housing market sensitivity to interest rates. Investment appeal hinges on execution of margin recovery and sector momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
